|
US6252052B1
(en)
*
|
1996-10-03 |
2001-06-26 |
Cornell Research Foundation, Inc |
Antibodies which bind to NY-ESO-1 cancer associated proteins, and hybridomas which produce these antibodies
|
|
US6417165B1
(en)
|
1988-03-27 |
2002-07-09 |
Ludwig Institute For Cancer Research |
NY-ESO-1-peptide derivatives, and uses thereof
|
|
US6723832B1
(en)
*
|
1996-10-03 |
2004-04-20 |
Ludwig Institute For Cancer Research |
Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
|
|
US7888100B2
(en)
*
|
1996-10-03 |
2011-02-15 |
Memorial Sloan-Kettering Cancer Research |
Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein
|
|
US6255470B1
(en)
*
|
1996-10-03 |
2001-07-03 |
Memorial Sloan-Kettering Cancer Center |
Isolated nucleic acid molecule encoding an esophageal cancer associated antigen
|
|
US6251603B1
(en)
|
1996-10-03 |
2001-06-26 |
Ludwig Institute For Cancer Research |
Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample
|
|
US6794131B1
(en)
|
1998-01-27 |
2004-09-21 |
Ludwig Institute For Cancer Research |
Lage-1 tumor associated nucleic acids
|
|
DK0970206T3
(da)
*
|
1997-01-27 |
2008-10-13 |
Ludwig Inst Cancer Res |
Lage-1-tumorassocierede nukleinsyrer
|
|
US6287756B1
(en)
|
1997-05-05 |
2001-09-11 |
Ludwig Institute For Cancer Research |
Methods for determining presence of cancer in a sample by determining expression of an SSX gene
|
|
US6673350B2
(en)
*
|
1997-05-05 |
2004-01-06 |
Ludwig Institute For Cancer Research |
Tumor associated peptide and uses thereof
|
|
US6994851B1
(en)
|
1997-07-10 |
2006-02-07 |
Mannkind Corporation |
Method of inducing a CTL response
|
|
US6977074B2
(en)
|
1997-07-10 |
2005-12-20 |
Mannkind Corporation |
Method of inducing a CTL response
|
|
ES2281935T3
(es)
*
|
1997-10-08 |
2007-10-01 |
The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services |
Antigeno cancerigeno humano ny eso-1/ca6 y gen que codifica para el mismo.
|
|
EP1806403A3
(en)
*
|
1997-10-08 |
2008-01-23 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Human cancer antigen NY ESO 1/CAG-3 and gene encoding same
|
|
US7084239B1
(en)
|
1997-10-08 |
2006-08-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Cancer peptides of NY-ESO-1/CAG-3
|
|
US7001999B1
(en)
*
|
1998-04-15 |
2006-02-21 |
Ludwig Institute For Cancer Research |
Tumor associated nucleic acids and uses therefor
|
|
US6140050A
(en)
*
|
1998-06-26 |
2000-10-31 |
Ludwig Institute For Cancer Research |
Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
|
|
US6800730B1
(en)
*
|
1998-10-02 |
2004-10-05 |
Ludwig Institute For Cancer Research |
Isolated peptides which bind to MHC class II molecules, and uses thereof
|
|
WO2000050595A2
(en)
*
|
1999-02-25 |
2000-08-31 |
Ivan Gout |
Nucleic acid molecules associated with melanoma and thyroid tumors
|
|
DE19949595A1
(de)
*
|
1999-10-14 |
2001-05-03 |
Deutsches Krebsforsch |
CTAGE-Genfamilie
|
|
CA2388337C
(en)
|
1999-10-22 |
2013-01-08 |
Aventis Pasteur Limited |
Method of inducing and/or enhancing an immune response to tumor antigens
|
|
US6689742B1
(en)
*
|
2000-02-25 |
2004-02-10 |
Chancellors, Masters And Scholars Of The University Of Oxford |
NY-ESO-1 peptide derivatives, and uses thereof
|
|
AU2001250828A1
(en)
*
|
2000-03-14 |
2001-09-24 |
The Johns Hopkins University School Of Medicine |
Immunogenic ovarian cancer genes
|
|
US6861234B1
(en)
|
2000-04-28 |
2005-03-01 |
Mannkind Corporation |
Method of epitope discovery
|
|
EP1752160A3
(en)
|
2001-04-06 |
2007-05-30 |
Mannkind Corporation |
Epitope sequences
|
|
WO2003008537A2
(en)
*
|
2001-04-06 |
2003-01-30 |
Mannkind Corporation |
Epitope sequences
|
|
EP1390387A4
(en)
*
|
2001-04-20 |
2004-12-08 |
Ludwig Inst Cancer Res |
TESTICLES CANCER ANTIGENS
|
|
US6794501B2
(en)
*
|
2001-05-04 |
2004-09-21 |
Ludwig Institute For Cancer Research |
Colon cancer antigen panel
|
|
US7803382B2
(en)
*
|
2001-05-04 |
2010-09-28 |
Ludwig Institute For Cancer Research Ltd. |
Method for inducing immune response to NY-CO-58
|
|
CN101024842A
(zh)
|
2001-11-07 |
2007-08-29 |
曼康公司 |
编码靶相关抗原表位的表达载体及其设计方法
|
|
NZ535425A
(en)
*
|
2002-03-13 |
2008-05-30 |
Biogen Idec Inc |
Anti-alphavbeta6 antibodies
|
|
AU2003270311A1
(en)
*
|
2002-09-06 |
2004-03-29 |
Mannkind Corporation |
Epitope sequences
|
|
WO2005000870A2
(en)
*
|
2003-05-30 |
2005-01-06 |
Ludwig Institute Of Cancer Research |
Isolated ny-eso-1 peptides which bind to hla class ii molecules and uses thereof
|
|
US7178491B2
(en)
*
|
2003-06-05 |
2007-02-20 |
Caterpillar Inc |
Control system and method for engine valve actuator
|
|
AU2004249254B2
(en)
|
2003-06-17 |
2010-07-08 |
Mannkind Corporation |
Combinations of tumor-associated antigens for the treatment of various types of cancers
|
|
WO2005033278A2
(en)
*
|
2003-09-30 |
2005-04-14 |
Ludwig Institute For Cancer Research |
In vivo efficacy of ny-eso-1 plus iscom
|
|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
|
WO2005114203A2
(en)
*
|
2004-05-20 |
2005-12-01 |
The Regents Of The University Of California |
Dominant b cell epitopes and methods of making and using thereof
|
|
US20060008468A1
(en)
*
|
2004-06-17 |
2006-01-12 |
Chih-Sheng Chiang |
Combinations of tumor-associated antigens in diagnostics for various types of cancers
|
|
CA2571168A1
(en)
*
|
2004-06-17 |
2006-01-26 |
Mannkind Corporation |
Mhc i-binding ssx-241-49 variants
|
|
US20060159689A1
(en)
*
|
2004-06-17 |
2006-07-20 |
Chih-Sheng Chiang |
Combinations of tumor-associated antigens in diagnostics for various types of cancers
|
|
PL1833506T3
(pl)
*
|
2004-12-29 |
2016-01-29 |
Mannkind Corp |
Zastosowanie kompozycji zawierających różne antygeny związane z nowotworem jako szczepionek przeciwnowotworowych
|
|
JP2008526763A
(ja)
*
|
2004-12-29 |
2008-07-24 |
マンカインド コーポレイション |
予防又は治療目的のｍｈｃクラスｉ拘束性エピトープに対する免疫応答の誘導、増強及び保持方法
|
|
SG162817A1
(en)
|
2005-06-17 |
2010-07-29 |
Mannkind Corp |
Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
|
|
NZ564359A
(en)
|
2005-06-17 |
2011-09-30 |
Mannkind Corp |
Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes
|
|
AU2006259221B8
(en)
|
2005-06-17 |
2013-02-07 |
Mannkind Corporation |
Multivalent entrain-and-amplify immunotherapeutics for carcinoma
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
US8309096B2
(en)
*
|
2007-01-15 |
2012-11-13 |
Glaxosmithkline Biologicals S.A. |
Fusion protein
|
|
WO2009046738A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
|
|
CN101888856B
(zh)
|
2007-11-07 |
2014-08-27 |
塞尔德克斯医疗公司 |
结合人树突和上皮细胞205(dec-205)的抗体
|
|
JP5779352B2
(ja)
|
2008-03-14 |
2015-09-16 |
サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー |
複製欠損フラビウイルスワクチンおよびワクチンベクター
|
|
SG174877A1
(en)
|
2009-03-17 |
2011-11-28 |
Mdxhealth Sa |
Improved detection of gene expression
|
|
GB0910046D0
(en)
|
2009-06-10 |
2009-07-22 |
Glaxosmithkline Biolog Sa |
Novel compositions
|
|
EA201690310A1
(ru)
|
2010-04-13 |
2016-12-30 |
Селлдекс Терапьютикс Инк. |
Антитела, связывающие cd27 человека, и их применение
|
|
PL3892295T3
(pl)
|
2011-05-24 |
2023-07-24 |
BioNTech SE |
Zindywidualizowane szczepionki przeciwnowotworowe
|
|
GB201116248D0
(en)
|
2011-09-20 |
2011-11-02 |
Glaxosmithkline Biolog Sa |
Liposome production using isopropanol
|
|
US8490054B2
(en)
|
2011-09-23 |
2013-07-16 |
The United States Of America As Represented By The Secretary Of The Army |
Software and related software tracking during software modification
|
|
NL2007536C2
(en)
|
2011-10-05 |
2013-04-08 |
Academisch Ziekenhuis Leiden Lumc |
Adjuvant compound.
|
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
WO2014074785A1
(en)
|
2012-11-08 |
2014-05-15 |
Ludwig Institute For Cancer Research Ltd. |
Methods of predicting outcome and treating breast cancer
|
|
EP3417874B1
(en)
|
2012-11-28 |
2024-09-11 |
BioNTech SE |
Individualized vaccines for cancer
|
|
WO2014140938A2
(en)
|
2013-03-14 |
2014-09-18 |
Centre Hospitalier Universitaire Vaudois |
Immunological methods
|
|
WO2014180490A1
(en)
|
2013-05-10 |
2014-11-13 |
Biontech Ag |
Predicting immunogenicity of t cell epitopes
|
|
PE20170441A1
(es)
|
2014-06-06 |
2017-04-26 |
Bristol Myers Squibb Co |
Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
|
|
CN113791220A
(zh)
|
2014-09-10 |
2021-12-14 |
豪夫迈·罗氏有限公司 |
免疫原性突变体肽筛选平台
|
|
WO2016045732A1
(en)
|
2014-09-25 |
2016-03-31 |
Biontech Rna Pharmaceuticals Gmbh |
Stable formulations of lipids and liposomes
|
|
WO2016128060A1
(en)
|
2015-02-12 |
2016-08-18 |
Biontech Ag |
Predicting t cell epitopes useful for vaccination
|
|
WO2016145085A2
(en)
|
2015-03-09 |
2016-09-15 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
|
DK3303396T5
(da)
|
2015-05-29 |
2024-10-07 |
Bristol Myers Squibb Co |
Antistoffer mod ox40 og anvendelser deraf
|
|
WO2017059902A1
(en)
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
|
AU2016356780A1
(en)
|
2015-11-19 |
2018-06-28 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
|
US12297266B2
(en)
|
2016-04-18 |
2025-05-13 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human CD40 and uses thereof
|
|
NL2018803B1
(en)
|
2017-04-27 |
2018-11-05 |
Academisch Ziekenhuis Leiden Handelend Onder De Naam Leids Univ Medisch Centrum/ H O D N Lumc |
Adjuvant compounds
|
|
WO2018224166A1
(en)
|
2017-06-09 |
2018-12-13 |
Biontech Rna Pharmaceuticals Gmbh |
Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
|
|
IL293698A
(en)
|
2019-12-11 |
2022-08-01 |
Molecular Partners Ag |
Recombinant peptide-mhc complex binding proteins, their production and use
|